Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients

Arthritis Care and Research

Volumn 69, Issue 12, 2017, Pages 1909-1914

  Rogers, Anna ^a   Chung, Lorinda ^a,b   Li, Shufeng ^a   Casciola Rosen, Livia ^c   Fiorentino, David F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 2 ANTIBODY; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; DNA BINDING PROTEIN; NUCLEAR MATRIX PROTEIN 2; TRANSCRIPTION FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CALCINOSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DERMATOMYOSITIS; DISEASE SEVERITY; DYSPHAGIA; ETHNIC DIFFERENCE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PERIPHERAL EDEMA; RETROSPECTIVE STUDY; SEX DIFFERENCE; SYMPTOMATOLOGY; TRANSLATION INITIATION; AGE; AGED; BLOOD; CALIFORNIA; COMPLICATION; EDEMA; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SKIN; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; BIOMARKERS; CALIFORNIA; DEGLUTITION DISORDERS; DERMATOMYOSITIS; DNA-BINDING PROTEINS; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MYALGIA; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SKIN; TRANSCRIPTION FACTORS;

EID: 85028022306     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23210     Document Type: Article

References (27)

1. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8–23.
2. Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 2007;18:1701–9.
3. Oddis C, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco JA. Clinical and serological characterisation of the anti–MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997;40 Suppl:139.
4. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti–MJ) to a 142-kDa protein. J Rheumatol 2009;36:2547–51.
5. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92:223–43.
6. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti–NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014;53:2204–8.
7. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807–14.
8. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K. Four dermatomyositis-specific autoantibodies, anti–TIF1γ, anti–NXP2, anti–SAE, and anti–MDA5, in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014;13:1211–9.
9. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013;65:2954–62.
10. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012;14:R97.
11. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710–3.
12. Betteridge Z, Gunawardena H, Chinoy H, Venkovsky J, Allard S, Gordon P, et al. Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis [abstract]. Arthritis Rheum 2009;60 Suppl:S304.
13. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014;150:724–9.
14. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 2012;51:1181–7.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
16. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002;20:387–408.
17. Anyanwu CO, Fiorentino D, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 2015;173:969–74.
18. Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One 2016;11:e0154746.
19. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015;42:1448–54.
20. Milisenda JC, Doti PI, Prieto-Gonzalez S, Grau JM. Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature. Semin Arthritis Rheum 2014;44:228–33.
21. Tu J, McLean-Tooke A, Junckerstorff R. Increasing recognition of dermatomyositis with subcutaneous edema: is this a poorer prognostic marker? Dermatol Online J 2014;20:21244.
22. Goussot R, Wettle C, Le Coz C, Cribier B, Lipsker D. Severe edematous dermatomyositis. Ann Dermatol Venereol 2016;143:202–9. In French.
23. Watanabe M, Natsuga K, Arita K, Abe R, Shimizu H. Generalized acute subcutaneous edema as a rare cutaneous manifestation of severe dermatomyositis [letter]. J Eur Acad Dermatol Venereol 2016;30:e151–2.
24. Mroue KH, Sharara NH, Rbeiz JG, Arayssi TK. A case of edematous dermatomyositis. J Rheumatol 2003;30:2722–3.
25. Zedan M, El-Ayouty M, Abdel-Hady H, Shouman B, El-Assmy M, Fouda A. Anasarca: not a nephrotic syndrome but dermatomyositis. Eur J Pediatr 2008;167:831–4.
26. Mitchell JP, Dennis GJ, Rider LG. Juvenile dermatomyositis presenting with anasarca: a possible indicator of severe disease activity. J Pediatr 2001;138:942–5.
27. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016;280:24–38.